| Abstract [eng] |
Multiple Sclerosis is a chronic auto inflammatory disease of the central nervous system. The disease has a wide range of symptoms depending on the area affected in the brain.(11) Spasticity is one of the most prevalent symptoms in patients with MS. There are certain problems that arise in the treatment of spasticity. Many patients experience severe side effects because of multimedication and treatment resistant spasticity appears to be a huge problem in patients.(1)(11)(48) With a new syndrome called Spasticity plus syndrome, problems like multimedication, severe side effects and other arising problems could be cured. A few pharmacological treatment options are available, including the typical antispastic agents tizanidine, baclofen, and diazepam. The off-label use of Gabapentin. Furthermore, botulinum toxin injection is a newer treatment option. Cannabinoid oral mucosal spray is used as add on therapy for spasticity in MS which is becoming more popular. (54) This systematic review aims to evaluate the efficacy and safety of different medical treatment options of spasticity in Multiple Sclerosis. Is the current available medical treatment of spasticity effective and safe for patients with MS and are there any new medical options for the future? After analyzing various articles and clinical trials, inconsistent effectiveness of different medical treatment options was seen. All medications like baclofen, tizanidine or oral mucosal cannabinoid spray had a positive effect on spasticity symptoms. Overall, the medical treatment for spasticity in MS is showing good results. |
